Keyphrases
Rheumatoid Arthritis Patients
100%
Severe Infection
100%
Population-based Cohort Study
100%
Biologic DMARDs
100%
Biological Disease-modifying Antirheumatic Drugs (bDMARDs)
100%
Infection Risk
60%
Tocilizumab
40%
Piedmont Region
20%
Italy
20%
Clinical Practice
20%
Rheumatoid Arthritis
20%
Hospitalization
20%
Co-payment
20%
Administrative Data
20%
Competing Risks
20%
Hospital Discharge Records
20%
Drug Treatment
20%
Counterweight
20%
Retrospective Cohort Study
20%
Inhibitor Drug
20%
Healthcare Database
20%
Treatment Interruption
20%
Tumour Necrosis Factor Inhibitor (TNFi)
20%
Abatacept
20%
New User
20%
Drug Claims
20%
Risk Model
20%
Subdistribution Hazard Ratio
20%
Medicine and Dentistry
Infection
100%
Rheumatoid Arthritis
100%
Cohort Analysis
100%
Disease-Modifying Antirheumatic Drug
100%
Inflammatory Arthritis
100%
Disease Modifying Antirheumatic Drug
62%
Tocilizumab
25%
Drug Therapy
12%
Hazard Ratio
12%
Retrospective Cohort Study
12%
Treatment Interruption
12%
TNF Inhibitor
12%
Abatacept
12%
Pharmacology, Toxicology and Pharmaceutical Science
Infection
100%
Rheumatoid Arthritis
100%
Cohort Study
100%
Inflammatory Arthritis
100%
Disease Modifying Antirheumatic Drug
62%
Tocilizumab
25%
Pharmacotherapy
12%
Tumor Necrosis Factor Inhibitor
12%
Abatacept
12%
Mathematics
Hazard Ratio
100%
Competing Risk
100%
Relevant Data
100%
Competing Risk Model
100%
Immunology and Microbiology
Inflammatory Arthritis
100%
Disease-Modifying Antirheumatic Drug
100%
Tocilizumab
40%
TNF Inhibitor
20%
Abatacept
20%